• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Continuous Glucose Monitoring Metrics vs HbA1C to Predict Adverse Outcomes in Type 1 Diabetes Pregnancies

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Meek et al. (Diabetes Care, 2021) assessed the predictive performance of HbA1C , continuous glucose monitoring (CGM) metrics and other glycemic laboratory markers to predict adverse maternal and perinatal outcomes

METHODS:

  • Prespecified secondary analysis of an RCT
  • Data source
    • The Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT Trial – See ‘Related ObG Topics’ below)
  • Participants
    • Pregnant women with type 1 diabetes
  • Study design
    • HbA1C, CGM data, and other biochemical markers (see below) were compared at 12, 24, and 34 weeks gestation using logistic regression and receiver operating characteristic (ROC) curves
    • Other laboratory biochemical markers: Glycated CD59 | 1,5-anhydroglucitol | Fructosamine | Glycated albumin
    • GCM metrics:
      • Mean glucose
      • Time in range (TIR) | 63 to 140 mg/dL (3.5–7.8 mmol/L)
      • Time above range (TAR): >140 mg/dL (>7.8 mmol/L)
  • Primary outcomes
    • Preeclampsia
    • Preterm delivery
    • Large for gestational age
    • Neonatal hypoglycemia
    • Admission to neonatal intensive care unit

RESULTS:

  • 157 women included in data analysis
  • At 24 weeks
    • HbA1C, CGM metrics, and other laboratory biomarkers were all significantly associated with obstetric and neonatal outcomes
  • Most CGM metrics were associated with ≥1 adverse outcome including
    • Preeclampsia | Preterm delivery | LGA | Neonatal hypoglycemia | NICU admission
  • More outcomes were associated with
    • CGM metrics during the first trimester
    • Biochemical markers during the third trimester
  • Some CGM metrics and laboratory markers were associated with preeclampsia at 24 weeks
  • HbA1C
    • Consistent predictor of suboptimal pregnancy outcomes
    • However, not associated with preeclampsia
  • The most consistently predictive CGM metrics were
    • TIR | TAR
  • Area under the ROC curve for CGM, laboratory biochemical markers, and HbA1C generally did not achieve AUROCs >0.7

CONCLUSION:

  • While some other laboratory biomarkers showed promise as predictors for adverse pregnancy outcomes in type 1 diabetes, they generally did not perform as well as HbA1C
  • The authors conclude

HbA1c was consistently associated with pregnancy outcomes, suggesting that despite the known limitations of HbA1c for assessing antenatal glycemia, it is still a critically important biomarker for obstetric and neonatal health outcomes

While other laboratory biomarkers demonstrated some promise, none were able to significantly increase the AUROC, showing, at best, comparable prediction to HbA1c alone

Learn More – Primary Sources:

Novel Biochemical Markers of Glycemia to Predict Pregnancy Outcomes in Women With Type 1 Diabetes

Now You Can Get Mobile-Friendly ObG Clinical Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Prepregnancy Diabetes: Does Better Glycemic Control Reduce the Risk for Adverse Events?
Does Treating Hyperglycemia Earlier in Pregnancy Improve Neonatal and Maternal Outcomes?
CONCEPTT Study: Time for Continuous Glucose Monitoring for All Pregnant Women with Type 1 Diabetes?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site